RPRX vs JNJ

For growth investors, Royalty Pharma plc (RPRX) is the stronger pick with 5.

1% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Royalty Pharma plc (RPRX) offers the better valuation at 28. 2x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Royalty Pharma plc (RPRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Royalty Pharma plc (RPRX) is the cheapest at 28.

2x versus Johnson & Johnson at 38. 8x. On forward P/E, Royalty Pharma plc is actually cheaper at 10. 4x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +48.

0%, compared to +33. 3% for Royalty Pharma plc (RPRX). Over 10 years, the gap is even starker: JNJ returned +136. 2% versus RPRX's +24. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Royalty Pharma plc's 0. 45β — meaning RPRX is approximately 697% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 92% for Royalty Pharma plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Royalty Pharma plc (RPRX) is pulling ahead at 5.

1% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Royalty Pharma plc grew EPS 24. 1% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, JNJ leads at 4. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Royalty Pharma plc (RPRX) is the more profitable company, earning 32.

4% net margin versus 15. 8% for Johnson & Johnson — meaning it keeps 32. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65. 6% versus 24. 9% for JNJ. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Royalty Pharma plc (RPRX) trades at 10.

4x forward P/E versus 19. 4x for Johnson & Johnson — 9. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JNJ: 11. 0% to $249. 27.

All stocks in this comparison pay dividends.

Johnson & Johnson (JNJ) offers the highest yield at 2. 2%, versus 1. 3% for Royalty Pharma plc (RPRX).

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +136. 2% 10Y return). Both have compounded well over 10 years (JNJ: +136. 2%, RPRX: +24. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.